Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours Β· Estimated delivery Sep 23 - Sep 28
A core part of Sophie's work is building MedExpress's Real-World Evidence (RWE) programme: learning systematically from patient outcomes to understand what works in practice, not just in clinical trials
GIP (Glucose-dependent Insulinotropic Polypeptide): Another incretin hormone produced in the intestines Stimulates insulin secretion from the pancreas Enhances fat metabolism Affects how the body stores and uses energy May amplify the appetite-suppressing effects of GLP-1 The Combined Effect: When both GLP-1 and GIP pathways are activated together: Stronger insulin response: better blood sugar control Enhanced fat burning: greater weight loss More appetite suppression: reduced food intake Slower gastric emptying: prolonged fullness (and potential problems) Clinical Advantages of Tirzepatide Greater Weight Loss: Clinical trials showed tirzepatide produced: Average weight loss: 20-25% of body weight Compared to semaglutide: 15-20% Some patients lost 30%+ of their starting weight Faster Results: Many patients report: Quicker onset of appetite suppression More rapid weight loss in the first months Stronger fullness sensation after meals Superior Glucose Control: For diabetic patients: Greater A1C reductions than semaglutide More patients reaching target A1C goals Fewer patients needing additional diabetes medications Potential Disadvantages and Risks 1
While it can be distracting, it is usually not cause for immediate concern
You want 503B pharmacy compounding rather than 503A
Can I switch back to Wegovy if Zepbound doesn't work
Like any DPP-4 inhibitor, this medication can only be used for type 2 diabetes
